Filing Details

Accession Number:
0001415889-21-002033
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-20 16:05:21
Reporting Period:
2021-04-16
Accepted Time:
2021-04-20 16:05:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1733294 Generation Bio Co. GBIO Pharmaceutical Preparations (2834) 814301281
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1814198 Matthew Stanton C/O Generation Bio Co., 301 Binney St
Cambridge MA 02142
Chief Scientific Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-04-16 1,500 $0.60 199,654 No 4 M Direct
Common Stock Disposition 2021-04-16 1,500 $28.03 198,154 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-04-16 1,500 $0.00 1,500 $0.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
28,194 2028-01-04 No 4 M Direct
Footnotes
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2020.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The option to purchase 87,584 shares of common stock was granted on January 5, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on January 4, 2019 and the remaining shares vesting in equal quarterly installments thereafter.